IMMUNIC, INC. (IMUX) GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - IMMUNIC INC

Financial Performance:

• No specific revenue, GAAP earnings, or margin figures disclosed as the company is pre-commercial.
• Recent capital structure includes a "Big Pipe" financing event announced in February 2024.
• A secondary tranche is triggered by the public disclosure of INSURE-1 and INSURE-2 results, with the potential to convert warrants into an additional $200 million in cash and equity within 30 days of disclosure.
• This capital infusion is projected to extend the company's cash runway into the back half of 2028.

Guidance and Future Outlook:

• Primary Catalyst: Awaiting pivotal phase 3 data for INSURE-1 and INSURE-2 (Relapsing MS) in December.
• Regulatory Milestone: Goal to file NDA in mid-2025 pending positive data, targeting a commercial launch in mid-2028.
• New Trial Initiation: Just announced the PROTECT-MS study for Progressive MS; first patient expected in the first half of 2025 (1,400 patients).
• Long-term Market View: Relapsing MS market in the US expected to grow to $25 billion by the 2030s; targets 4-5% market share to generate $1 billion in sales.
• Strategic Pivot: Transitioning from a pure development-stage entity to a pre-commercial organization with a specific mandate to commercialize lead assets.

Business Segments and Product Lines:

• Lead Asset: Vitaflumate Calcium (once-daily oral tablet).
• Dual Mechanism of Action:
  1. DHODH Inhibition: Provides neuroinflammatory control (proven pathway).
  2. NeuroOne (NLRP1) Activation: A novel, first-in-class neuroprotective mechanism directly targeting neuronal repair, resilience, and survival (unmet need not addressed by current therapies).
• Clinical Trial Portfolio:
  • INSURE-1 & INSURE-2: Twin pivotal phase 3 studies in Relapsing MS (2,221 patients total); primary endpoint is time to first relapse.
  • EMPHASIS: Phase 2 Relapsing MS study showed 42% risk reduction in relapses and a 76% reduction in Gadolinium-enhancing lesions.
  • CALIPER: Phase 2 Progressive MS study; missed primary endpoint (whole-brain atrophy) but showed nominal statistical benefit on "slowly expanding lesions" and clinical improvement in patients with no inflammatory activity.
  • PROTECT-MS: Phase 3 study for non-active progressive MS, enrolling patients with no evidence of inflammation at baseline.

Market and Competitive Landscape:

• Differentiation: Positioned as a potential best-in-class oral therapy with a superior safety/tolerability profile compared to current DHO-DH inhibitors (e.g., teriflunomide) and potential future BTK inhibitors.
• Safety Profile: Features a 30-hour half-life (vs. 16-19 days for teriflunomide), clearing the system in <10 days; lacks off-target effects like alopecia, embryofetal toxicity, and severe liver issues associated with competitors.
• Market Need: Addresses the "long-term anti-CD20" dilemma; patients typically switch off anti-CD20s (Ocrevus/Kevzara) after 3-8 years due to infection risks or lack of approved switch therapies with better safety profiles.
• Target Audience: Approximately 90,000 patients annually in the US (switchers and new initiators) among the 300,000 treated with disease-modifying therapies.

Risks and Challenges:

• Binary Catalyst Risk: The company's immediate valuation and commercial viability hinge entirely on the success of the December phase 3 readouts.
• Trial Complexity: Transitioning from Phase 2 to Phase 3 often involves "drift" in efficacy; while baseline demographics are consistent, statistical success is not guaranteed.
• Competitive Pressure: Potential competition from emerging BTK inhibitors and continued dominance of anti-CD20 monoclonal antibodies.
• Commercial Execution: Requires building a full commercial infrastructure (sales force, marketing, patient advocacy) from scratch in a highly competitive market.

Management Commentary and Tone:

• Confidence: Leadership expresses high confidence in the "de-risked" nature of the primary phase 3 outcomes, citing the strong Phase 2 Gadolinium reduction data as a predictor.
• Transparency: Management openly acknowledged the CALIPER study missing its primary endpoint (brain atrophy) but reframed it based on meta-analysis data showing poor predictor status of that metric.
• Strategic Clarity: Eric Lundgren (CEO) and Jason Tardio (COO) emphasize a decisive pivot to commercialization, evidenced by recent board changes and hiring of VP-level marketing and patient advocacy talent.
• Safety Focus: Repeatedly highlighted the "benign" safety database (3,500+ patients, some on drug for 7 years) as a critical commercial differentiator.

Analyst Questions and Answers:

• Q: Interim IDMC analysis implications?
  • A: The Interim Data Monitoring Committee (IDMC) confirmed the study was not futile and that powering assumptions remain adequate, indicating a positive signal to continue the trial to completion.
• Q: Phase 2 to Phase 3 efficacy translation?
  • A: Management expects the 42% relapse risk reduction to hold, acknowledging potential variance but maintaining confidence in the "best-in-class" benefit-risk package.
• Q: Mechanism familiarity (NLRP1/NeuroOne)?
  • A: Key Opinion Leaders (KOLs) are described as "excited" about the neuroprotective thesis, which addresses the critical unmet need for slowing disability progression.
• Q: Launch and Commercial Plans?
  • A: Company intends to launch orally and independently in the US (no licensing/partnership mentioned for launch).
• Q: Capital needs?
  • A: With the $200M potential warrant conversion, the company has sufficient runway for the upcoming phase 3 trials and pre-launch activities.

Other Key Points:

• Corporate Governance: Significant turnover in the Board of Directors and addition of executive talent reflects the strategic shift from R&D to commercial readiness.
• Half-Life Advantage: Emphasized that Vitafumate's rapid clearance (<10 days) mitigates risks for women of childbearing age compared to teriflunomide (which can remain in the system for >2 years).
• Statistical Innovation: The phase 3 statistical plan for progression endpoints utilizes a "Net Clinical Benefit" approach (combining improvement, stability, and worsening) to extract more signal from EDSS data.